PainChek receives $1.123 million R&D tax incentive refund
Filed with ASX · · 2 pages · English
Summary by 6ix AI
PainChek Ltd has announced the receipt of a research and development tax incentive refund, which strengthens its cash position and supports ongoing product development and commercialization efforts. This announcement highlights PainChek's commitment to advancing its AI-enabled pain assessment platform and expanding its technology for use in children.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from PainChek
- US MedTech leader Karen Holzberger appointed CEO
- CEO Transition
- PainChek secures A$5.5m note to fund US expansion
- Landmark Sabra North America deployment targeting 20k beds
- PainChek reports material sales momentum in UK
Later from PainChek
- Quarterly Activities/Appendix 4C Cash Flow Report
- Change of Director's Interest Notice x 4
- Update - Notification regarding unquoted securities - PCK
- PainChek Investor Webinar
- Appendix 4E and Financial Report
Follow PainChek into a list and get an email when it puts out news.
Follow PainChek